{"result": {"id": "87801f8e-58a8-4447-94c7-0d221de7de5e", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>EMPA-KIDNEY COLLABORATIVE GROUP<|>ORGANIZATION<|>A research group involved in studying the effects of Empagliflozin in patients with chronic kidney disease>  \n##  \n(\"entity\"<|>HERINGTON WG<|>PERSON<|>A researcher associated with the EMPA-KIDNEY Collaborative Group>  \n##  \n(\"entity\"<|>STAPLIN N<|>PERSON<|>A researcher associated with the EMPA-KIDNEY Collaborative Group>  \n##  \n(\"entity\"<|>HEERSPINK HJL<|>PERSON<|>A researcher involved in studies on Dapagliflozin in patients with chronic kidney disease>  \n##  \n(\"entity\"<|>STEFÁNSSON BV<|>PERSON<|>A researcher involved in studies on Dapagliflozin in patients with chronic kidney disease>  \n##  \n(\"entity\"<|>CORREA-ROTTER R<|>PERSON<|>A researcher involved in studies on Dapagliflozin in patients with chronic kidney disease>  \n##  \n(\"entity\"<|>JONGS N<|>PERSON<|>A researcher involved in the DAPA-CKD trial studying Dapagliflozin's effect on urinary albumin excretion>  \n##  \n(\"entity\"<|>GREENE T<|>PERSON<|>A researcher involved in the DAPA-CKD trial studying Dapagliflozin's effect on urinary albumin excretion>  \n##  \n(\"entity\"<|>CHERTOW GM<|>PERSON<|>A researcher involved in the DAPA-CKD trial studying Dapagliflozin's effect on urinary albumin excretion>  \n##  \n(\"entity\"<|>AGARWAL R<|>PERSON<|>A researcher involved in the FIDELITY pooled analysis on cardiovascular and kidney outcomes with Finerenone>  \n##  \n(\"entity\"<|>FILIPPATOS G<|>PERSON<|>A researcher involved in the FIDELITY pooled analysis on cardiovascular and kidney outcomes with Finerenone>  \n##  \n(\"entity\"<|>PITT B<|>PERSON<|>A researcher involved in the FIDELITY pooled analysis on cardiovascular and kidney outcomes with Finerenone>  \n##  \n(\"entity\"<|>FRIED LF<|>PERSON<|>A researcher involved in studies on combined angiotensin inhibition for diabetic nephropathy>  \n##  \n(\"entity\"<|>EMANUELE N<|>PERSON<|>A researcher involved in studies on combined angiotensin inhibition for diabetic nephropathy>  \n##  \n(\"entity\"<|>ZHANG JH<|>PERSON<|>A researcher involved in studies on combined angiotensin inhibition for diabetic nephropathy>  \n##  \n(\"entity\"<|>MANCIA G<|>PERSON<|>A researcher involved in multiple hypertension-related studies, including white-coat hypertension>  \n##  \n(\"entity\"<|>FACCHETTI R<|>PERSON<|>A researcher involved in multiple hypertension-related studies, including white-coat hypertension>  \n##  \n(\"entity\"<|>BOMBELLI M<|>PERSON<|>A researcher involved in multiple hypertension-related studies, including white-coat hypertension>  \n##  \n(\"entity\"<|>KLEINERT HD<|>PERSON<|>A researcher involved in studies on home blood pressure measurement in mild hypertension>  \n##  \n(\"entity\"<|>HARSHFIELD GA<|>PERSON<|>A researcher involved in studies on home blood pressure measurement in mild hypertension>  \n##  \n(\"entity\"<|>PICKERING TG<|>PERSON<|>A researcher involved in studies on home blood pressure measurement in mild hypertension>  \n##  \n(\"entity\"<|>CAREY RM<|>PERSON<|>A researcher involved in studies on resistant hypertension>  \n##  \n(\"entity\"<|>CALHOUN DA<|>PERSON<|>A researcher involved in studies on resistant hypertension>  \n##  \n(\"entity\"<|>BAKRIS GL<|>PERSON<|>A researcher involved in studies on resistant hypertension>  \n##  \n(\"entity\"<|>SAUNDERS A<|>PERSON<|>A researcher involved in studies on white-coat hypertension and arterial stiffness>  \n##  \n(\"entity\"<|>NUREDINI GN<|>PERSON<|>A researcher involved in studies on white-coat hypertension and arterial stiffness>  \n##  \n(\"entity\"<|>KIRKHAM FA<|>PERSON<|>A researcher involved in studies on white-coat hypertension and arterial stiffness>  \n##  \n(\"entity\"<|>SIVÉN SS<|>PERSON<|>A researcher involved in the Finn-Home study on white-coat and masked hypertension>  \n##  \n(\"entity\"<|>NIIRANEN TJ<|>PERSON<|>A researcher involved in the Finn-Home study on white-coat and masked hypertension>  \n##  \n(\"entity\"<|>KANTOLA IM<|>PERSON<|>A researcher involved in the Finn-Home study on white-coat and masked hypertension>  \n##  \n(\"entity\"<|>CUSPIDI C<|>PERSON<|>A researcher involved in studies on nocturnal blood pressure and white-coat hypertension>  \n##  \n(\"entity\"<|>PAOLETTI F<|>PERSON<|>A researcher involved in studies on nocturnal blood pressure and white-coat hypertension>  \n##  \n(\"entity\"<|>TADIC M<|>PERSON<|>A researcher involved in studies on nocturnal blood pressure and white-coat hypertension>  \n##  \n(\"entity\"<|>ASAYAMA K<|>PERSON<|>A researcher involved in studies on white-coat and masked hypertension>  \n##  \n(\"entity\"<|>THIJS L<|>PERSON<|>A researcher involved in studies on white-coat and masked hypertension>  \n##  \n(\"entity\"<|>LI Y<|>PERSON<|>A researcher involved in studies on white-coat and masked hypertension>  \n##  \n(\"entity\"<|>HUANG Y<|>PERSON<|>A researcher involved in studies on white-coat hypertension as a risk factor for cardiovascular diseases>  \n##  \n(\"entity\"<|>HUANG W<|>PERSON<|>A researcher involved in studies on white-coat hypertension as a risk factor for cardiovascular diseases>  \n##  \n(\"entity\"<|>MAI W<|>PERSON<|>A researcher involved in studies on white-coat hypertension as a risk factor for cardiovascular diseases>  \n##  \n(\"entity\"<|>FRANKLIN SS<|>PERSON<|>A researcher involved in studies on the cardiovascular risk of white-coat hypertension>  \n##  \n(\"relationship\"<|>HERINGTON WG<|>EMPA-KIDNEY COLLABORATIVE GROUP<|>Herrington WG is a researcher associated with the EMPA-KIDNEY Collaborative Group<|>8>  \n##  \n(\"relationship\"<|>STAPLIN N<|>EMPA-KIDNEY COLLABORATIVE GROUP<|>Staplin N is a researcher associated with the EMPA-KIDNEY Collaborative Group<|>8>  \n##  \n(\"relationship\"<|>HEERSPINK HJL<|>STEFÁNSSON BV<|>Both researchers collaborated on studies about Dapagliflozin in chronic kidney disease<|>6>  \n##  \n(\"relationship\"<|>HEERSPINK HJL<|>CORREA-ROTTER R<|>Both researchers collaborated on studies about Dapagliflozin in chronic kidney disease<|>6>  \n##  \n(\"relationship\"<|>JONGS N<|>GREENE T<|>Both researchers collaborated on the DAPA-CKD trial<|>6>  \n##  \n(\"relationship\"<|>JONGS N<|>CHERTOW GM<|>Both researchers collaborated on the DAPA-CKD trial<|>6>  \n##  \n(\"relationship\"<|>AGARWAL R<|>FILIPPATOS G<|>Both researchers collaborated on the FIDELITY pooled analysis<|>6>  \n##  \n(\"relationship\"<|>AGARWAL R<|>PITT B<|>Both researchers collaborated on the FIDELITY pooled analysis<|>6>  \n##  \n(\"relationship\"<|>MANCIA G<|>FACCHETTI R<|>Both researchers collaborated on multiple hypertension-related studies<|>7>  \n##  \n(\"relationship\"<|>MANCIA G<|>BOMBELLI M<|>Both researchers collaborated on multiple hypertension-related studies<|>7>  \n##  \n(\"relationship\"<|>CUSPIDI C<|>PAOLETTI F<|>Both researchers collaborated on studies about nocturnal blood pressure<|>6>  \n##  \n(\"relationship\"<|>CUSPIDI C<|>TADIC M<|>Both researchers collaborated on studies about nocturnal blood pressure<|>6>  \n##  \n(\"relationship\"<|>ASAYAMA K<|>THIJS L<|>Both researchers collaborated on studies about white-coat and masked hypertension<|>6>  \n##  \n(\"relationship\"<|>ASAYAMA K<|>LI Y<|>Both researchers collaborated on studies about white-coat and masked hypertension<|>6>  \n##  \n(\"relationship\"<|>HUANG Y<|>HUANG W<|>Both researchers collaborated on studies about white-coat hypertension<|>6>  \n##  \n(\"relationship\"<|>HUANG Y<|>MAI W<|>Both researchers collaborated on studies about white-coat hypertension<|>6>  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558943, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 2168, "prompt_tokens": 2964, "total_tokens": 5132, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 1172}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: rophy as determined with echocardiographyin hypertensive patients: anetworkmeta-analysisofrandomizedcontrolledtrials [J]. J Clin Hypertens(Greenwich) ,2020,22(12) :2175-2183.\n[396]  TakamiT, HoshideS, KarioK.  Differentialimpactofantihy- pertensivedrugson cardiovascularremodeling: a review offind- ings andperspectivesforHFpEFprevention[J]. HypertensRes,  2022,45(1) :53-60.\n[397]  Heerspink HJL, Stefánsson BV, Correa-RotterR, etal. Dapa- gliflozin in patients with chronic kidney disease[J]. N EnglJ Med,2020,383(15) :1436-1446.\n[398]  The EMPA-KIDNEY Collaborative Group,  Herrington WG,  StaplinN, et al.  Empagliflozin in patients with chronic kidney disease[J]. N EnglJ Med,2023,388(2) :117-127.\n[399] JongsN, GreeneT, Chertow GM, etal. Effectofdapagliflozin\n\n\n\non urinary albumin excretioninpatientswithchronickidneydis- easewith and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial[J].  Lancet Diabetes Endocrinol,  2021,9(11) :755-766.\n[400]  AgarwalR, FilippatosG, PittB, etal. Cardiovascularand kid- ney outcomes with finerenone in patients with type 2 diabetes and chronickidneydisease: the FIDELITY pooled analysis[J].   EurHeartJ,2022,43(6) :474-484.\n[401]  FriedLF, EmanueleN, ZhangJH, etal. Combinedangiotensin inhibition forthetreatmentofdiabeticnephropathy[J]. NEnglJ Med,2013,369(20) :1892-1903.\n[402]  Mancia G, FacchettiR, BombelliM, et al.  White-coathyper- tension:   pathophysiological and  clinical  aspects:   excellence awardforhypertensionresearch2020[J]. Hypertension,2021,78\n(6) :1677-1688.\n[403]  KleinertHD, HarshfieldGA, PickeringTG, etal. Whatisthe valueofhomebloodpressuremeasurementinpatientswithmild hypertension?  [J]. Hypertension,1984,6(4) :574-578.\n[404]  CareyRM, CalhounDA, BakrisGL, etal. Resistanthyperten- sion: detection, evaluation, and management: ascientificstate- mentfrom the American HeartAssociation[J]. Hypertension,  2018,72(5) :e53-e90.\n[405]  SaundersA, NurediniGN, Kirkham FA, etal. White-coathy- pertension/effectis associated with higher arterial stiffness and strokeevents[J]. J Hypertens,2022,40(4) :758-764.\n[406]  ManciaG, BombelliM, FacchettiR, et al.  Long-term risk of sustained hypertension in white-coat or masked hypertension [J]. Hypertension,2009,54(2) :226-232.\n[407]  Sivén SS,  Niiranen TJ,  Kantola IM,  et al.  White-coat and masked hypertension asrisk factorsforprogression to sustained hypertension: the Finn-Home study[J]. J Hypertens, 2016, 34\n(1) :54-60.\n[408]  ManciaG, BombelliM, BrambillaG, etal. Long-term prognos- ticvalueofwhite coathypertension: an insightfrom diagnostic useofboth ambulatory and homeblood pressuremeasurements [J]. Hypertension,2013,62(1) :168-174.\n[409]  CuspidiC, PaolettiF, TadicM, et al.  Nocturnal blood pres- sure: thedark sideofwhite-coathypertension[J]. J Hypertens,  2020,38(12) :2404-2408.\n[410]  AsayamaK, ThijsL, LiY, etal. Settingthresholdstovarying blood pressuremonitoringintervalsdifferentially affectsrisk es- timates associated with white-coat and masked hypertension in thepopulation[J]. Hypertension,2014,64(5) :935-942.\n[411]  ManciaG, FacchettiR, CuspidiC, etal. Limitedreproducibility ofMUCH andWUCH: evidence from the ELSA study[J]. Eur HeartJ,2020,41(16) :1565-1571.\n[412]  HuangY, HuangW , MaiW , etal. White-coathypertension is arisk factorforcardiovasculardiseasesand totalmortality[J]. J Hypertens,2017,35(4) :677-688.\n[413]  Franklin SS, Thijs L, Asayama K, et al.  The cardiovascular risk ofwhite-coathypertension[J]. JAm CollCardiol, 2016, 68\n(19) :2033-204\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_2472e888bd3da437d415f375ece94f3195fb104cc95e02f16e364c85ef2ff3b5_v2"}